Generation of Toxoplasma gondii GRA1 protein and DNA vaccine loaded chitosan particles:: preparation, characterization, and preliminary in vivo studies

被引:89
作者
Bivas-Benita, M
Laloup, M
Versteyhe, S
Dewit, J
De Braekeleer, J
Jongert, E
Borchard, G
机构
[1] Leiden Amsterdam Ctr Drug Res, Div Pharmaceut Technol, NL-2300 RA Leiden, Netherlands
[2] Natl Inst Criminalist & Criminol, Toxicol Lab, B-1120 Brussels, Belgium
[3] Pasteur Inst Brussels, Toxoplasma Res Unit, B-1180 Brussels, Belgium
关键词
mucosal vaccination; toxoplasmosis; GRA-1; DNA vaccine; chitosan;
D O I
10.1016/S0378-5173(03)00377-6
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Chitosan microparticles as carriers for GRA-1 protein vaccine were prepared and characterized with respect to loading efficiency and GRA-1 stability after short-term storage. Chitosan nanoparticles as carriers for GRA-1 pDNA vaccine were prepared and characterized with respect to size, zeta potential, and protection of the pDNA vaccine against degradation by DNase I. Both protein and pDNA vaccine preparations were tested with regard to their potential to elicit GRA-1-specific immune response after intragastric administration using different prime/boost regimen. The immune response was measured by determination of IgG2a and IgG1 antibody titers. It was shown that priming with GRA1 protein vaccine loaded chitosan particles and boosting with GRA1 pDNA vaccine resulted in high anti-GRA1 antibodies, characterized by a mixed IgG2a/IgG1 ratio. These results showed that oral delivery of vaccines using chitosan as a carrier material appears to be beneficial for inducing an immune response against Toxoplasma gondii. The type of immune response, however, will largely depend on the prime/boost regimen and the type of vaccine used. (C) 2003 Elsevier B. V. All rights reserved.
引用
收藏
页码:17 / 27
页数:11
相关论文
共 28 条
[1]   EFFECT OF CHITOSAN ON THE PERMEABILITY OF MONOLAYERS OF INTESTINAL EPITHELIAL-CELLS (CACO-2) [J].
ARTURSSON, P ;
LINDMARK, T ;
DAVIS, SS ;
ILLUM, L .
PHARMACEUTICAL RESEARCH, 1994, 11 (09) :1358-1361
[2]   Intranasal immunization with SAG1 and nontoxic mutant heat-labile enterotoxins protects mice against Toxoplasma gondii [J].
Bonenfant, C ;
Dimier-Poisson, I ;
Velge-Roussel, F ;
Buzoni-Gatel, D ;
Del Giudice, G ;
Rappuoli, R ;
Bout, D .
INFECTION AND IMMUNITY, 2001, 69 (03) :1605-1612
[3]   ORAL IMMUNIZATION WITH TOXOPLASMA-GONDII ANTIGENS IN ASSOCIATION WITH CHOLERA-TOXIN INDUCES ENHANCED PROTECTIVE AND CELL-MEDIATED-IMMUNITY IN C57BL/6 MICE [J].
BOURGUIN, I ;
CHARDES, T ;
BOUT, D .
INFECTION AND IMMUNITY, 1993, 61 (05) :2082-2088
[4]   Intranasal immunization with SAG1 protein of Toxoplasma gondii in association with cholera toxin dramatically reduces development of cerebral cysts after oral infection [J].
Debard, N ;
BuzoniGatel, D ;
Bout, D .
INFECTION AND IMMUNITY, 1996, 64 (06) :2158-2166
[5]   Regulation and function of T-cell-mediated immunity during Toxoplasma gondii infection [J].
Denkers, EY ;
Gazzinelli, RT .
CLINICAL MICROBIOLOGY REVIEWS, 1998, 11 (04) :569-+
[6]   T lymphocyte-dependent effector mechanisms of immunity to Toxoplasma gondii [J].
Denkers, EY .
MICROBES AND INFECTION, 1999, 1 (09) :699-708
[7]  
Dubey J. P., 1988, TOXOPLASMOSIS ANIMAL
[8]  
DUQUESNE V, 1991, CLIN EXP IMMUNOL, V84, P527
[9]   Purification of His-tagged proteins by immobilized chelate affinity chromatography: The benefits from the use of organic solvent [J].
Franken, KLMC ;
Hiemstra, HS ;
van Meijgaarden, KE ;
Subronto, Y ;
den Hartigh, J ;
Ottenhoff, THM ;
Drijfhout, JW .
PROTEIN EXPRESSION AND PURIFICATION, 2000, 18 (01) :95-99
[10]   CONGENITAL TOXOPLASMOSIS - PREVENTION, SCREENING AND TREATMENT [J].
HOLLIMAN, RE .
JOURNAL OF HOSPITAL INFECTION, 1995, 30 :179-190